1
Clinical Trials associated with E1M184V peptide vaccine(CC)A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance
RATIONALE: Vaccines made from peptides may help the body build an effective immune response. Incomplete Freund's adjuvant may stimulate the immune system in different ways and may help the vaccine work better. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF may be an effective treatment for patients with HIV.
PURPOSE: This clinical trial is studying how well giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF works in treating patients with HIV.
100 Clinical Results associated with E1M184V peptide vaccine(CC)
100 Translational Medicine associated with E1M184V peptide vaccine(CC)
100 Patents (Medical) associated with E1M184V peptide vaccine(CC)
100 Deals associated with E1M184V peptide vaccine(CC)